Business

Zymeworks Announces Participation in Upcoming Conferences

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI • Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT) VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasd

articleZymeworks Inc.December 2, 20254/company/zymeworks-inc-common-stock/news/zymeworks-announces-participation-upcoming-conferences-210500691
Zymeworks Announces Participation in Upcoming Conferences

About this update from Zymeworks Inc.

[{"type":"image","alt":"Zymeworks Inc.","displaySize":"","headline":null,"caption":"Zymeworks Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Mr3NL5l3JfRng99mnVVlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f","width":300,"height":107}},"lazy":false},{"type":"text","content":"• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz","length":168,"tagName":"p"},{"type":"text","content":"• Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI","length":141,"tagName":"p"},{"type":"text","content":"• Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT)","length":105,"tagName":"p"},{"type":"text","content":"VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences.","length":316,"tagName":"p"},{"type":"text","content":"ASCO Gastrointestinal Cancers SymposiumJanuary 8-10, 2026San Francisco, CA","length":76,"tagName":"p"},{"type":"text","content":"Zymeworks Presentation","length":22,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:33%;width:33%;min-width:33%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Presentation Title","length":18,"tagName":"p","attribs":{}}]},{"style":"max-width:34%;width:34%;min-width:34%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Authors","length":7,"tagName":"p","attribs":{}}]},{"style":"max-width:33%;width:33%;min-width:33%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;vertical-align:t...

More updates from Zymeworks Inc.

Poster Sessionhealthcare assetsbiotechnology companyZymeworksAbstract numberSan Francisco, CARobin Kate KelleyOral PresentationTakako Eguchi NakajimaJong Gwang KimMichael SchenkerRichard Finn